Clopidogrel as an antiplatelet agent in transplant heart coronary stenting.
Clopidogrel is increasingly used as an antiplatelet agent along with aspirin in coronary stenting due to its safety profile and clinical efficacy. This report describes a case of successful direct coronary stenting in a transplanted heart with the use of clopidogrel and aspirin therapy. Vessel patency was preserved with no evidence of in stent restenosis on 4-month follow-up angiography.
Mahadevan
Vaikom S
VS
Regional Medical Cardiology Centre, Royal Victoria Hospital, Grosvenor Rd., Belfast, BT12 6BA, United Kingdom. vsm@ntlworld.com
Khan
Mazhar M
MM
Adgey
Jennifer A A
JA
D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D003328:Coronary Thrombosis / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D016027:Heart Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin